Valneva SE (FR:VLA)
:VLA
Want to see FR:VLA full AI Analyst Report?
VLA Stock Chart & Stats
€2.59
-€0.05(-2.40%)
At close: 4:00 PM EST
€2.59
-€0.05(-2.40%)
Day’s Range― - ―
52-Week Range€2.32 - €5.42
Previous CloseN/A
Volume233.04K
Average Volume (3M)1.29M
Market Cap
€398.39M
Enterprise Value€507.17M
Total Cash (Recent Filing)€109.65M
Total Debt (Recent Filing)€207.25M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
May 07, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding172,213,490
10 Day Avg. Volume925,642
30 Day Avg. Volume1,288,661
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.60Price Target Upside116.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.41
Revenue Forecast (FY)€165.66M
Bulls Say, Bears Say
Bulls Say
Proprietary Product Revenue GrowthConsistent growth in proprietary vaccine sales—notably IXIARO—signals a durable recurring revenue base from owned products and market access in travel and public-health channels. This strengthens margins potential and reduces reliance on one-off collaboration income over the medium term.
Improved Liquidity And RefinancingA ~EUR110m cash balance and successful refinancing materially lower near-term funding risk and extend runway for R&D and commercialization. This gives management time to execute pipeline milestones and cash‑burn reduction initiatives without immediate dilutive financing, improving strategic optionality.
High‑value Late‑stage Pipeline Catalyst (Lyme)A positive Phase III Lyme readout would be a structural game‑changer: it could unlock significant commercial upside, trigger combined milestone payments ($143m upon first commercial sales) and broaden Valneva's proprietary franchise, materially improving future revenue growth and partner leverage.
Bears Say
Sizable Operating And Net LossesLarge recurring operating and net losses erode equity and constrain reinvestment capacity. Persistent negative EBITDA means the business must either generate strong product cash flow or raise external capital, creating dilution and restricting long‑term margin recovery if losses persist.
Inventory Write‑offs And Idle Manufacturing CostsInventory impairments and ~EUR10.8m of idle capacity indicate structural manufacturing inefficiencies and underused plants. These fixed-cost burdens depress gross margins and cash flow until utilization improves or assets are repurposed, making margins and profitability fragile over the medium term.
Revenue Mix Shift And Partner/regulatory DependencePlanned reduction in third‑party sales and reliance on partners (Pfizer study control, DoD supply timing, ACIP decisions) reduce revenue diversification and amplify execution risk. Slower or delayed partner/regulatory actions could prolong cash burn and impede sustained top‑line recovery.
Valneva News
VLA FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest stock price was €2.31 and its highest was €5.42 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €398.39M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is May 07, 2026 which is in 9 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on Mar 18, 2026. The company reported -€0.293 earnings per share for the quarter, missing the consensus estimate of -€0.155 by -€0.138.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Undervalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.07.
How many shares outstanding does Valneva SE have?
Valneva SE has 172,213,490 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.293 in its last earnings report, missing expectations of -€0.155. Following the earnings report the stock price went up 1.905%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in FR:VLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
VLA Stock 12 Month Forecast
Average Price Target
€5.60
▲(116.22% Upside)
Technical Analysis
Options Prices
Currently, No data available
---